Skip to main content
Caplight Logo









APIM Therapeutics AS

APIM Therapeutics AS

Private
TrondheimHealthcare & Life Scienceshttps://apimtherapeutics.com/

Last Round

Private Equity

May 18, 2021

Total Funding Raised

$540,000

Company Overview

APIM Therapeutics AS is a biotechnology company that develops first-in-class peptide therapeutics targeting PCNA to disrupt cellular stress responses and overcome cancer treatment resistance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

peptide therapeuticsoncologyPCNAproliferating cell nuclear antigencancer drug developmentbiotechATX-101drug discoveryclinical-stage biotechsolid tumor treatmentcancer resistanceprecision medicinedrug out-licensingpharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

APIM Therapeutics AS Comparables

Compare APIM Therapeutics AS with similar companies based on industry and business-model similarity.

APIM Therapeutics AS comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RLL, LLC
83%
FoRx Therapeutics
71%
Artios Pharma
66%

APIM Therapeutics AS Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityMay 18, 2021
VC RoundDec 1, 2017
VC RoundOct 17, 2012
SeedNov 10, 2011
SeedMar 21, 2011
Seed
May 27, 2010

APIM Therapeutics AS Investors

Notable investors and investment history

APIM Therapeutics AS investors
InvestorRounds
Birk VentureVC Round, Seed
InvestinorVC Round
Trond Mohn Research FoundationVC Round
Sarsia SeedSeed
SarsiaSeed, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 4, 2026

    Monthly visitors grew 95% MoM.

  • Jan 9, 2026

    Monthly visitors grew 123% MoM, reaching 984.

APIM Therapeutics AS Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

APIM Therapeutics AS Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about APIM Therapeutics AS's valuation, stock price, and market status.

Firmographic Details

HeadquartersTrondheim
Employee Range7
Year Founded2009
Last FundingMay 18, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?